However, expression of genes involved in the E2F3 pathway is associated with increased chemotherapy sensitivity among ER-negative tumors only, whereas a mutant p53 signature and the expression of ER-related genes are associated with lower chemotherapy sensitivity in ER-positive breast tumors [31]. The gene discussed is ESR1; the disease is breast neoplasm.